CD40 Agonist Antibodies in Cancer Immunotherapy

Volume: 71, Issue: 1, Pages: 47 - 58
Published: Jan 27, 2020
Abstract
CD40 is a cell-surface member of the TNF (tumor necrosis factor) receptor superfamily. Upon activation, CD40 can license dendritic cells to promote antitumor T cell activation and re-educate macrophages to destroy tumor stroma. Numerous agonist CD40 antibodies of varying formulations have been evaluated in the clinic and found to be tolerable and feasible. Administration is associated with mild to moderate (but transient) cytokine release...
Paper Details
Title
CD40 Agonist Antibodies in Cancer Immunotherapy
Published Date
Jan 27, 2020
Volume
71
Issue
1
Pages
47 - 58
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.